Medconn Glycated Hemoglobin Test system

The Medconn Glycated Hemoglobin Test System is an ion-exchange HPLC analyzer that quantitatively measures hemoglobin A1c (HbA1c) in human whole blood or hemolysate. Results are reported in both NGSP (%) and IFCC (mmol/mol) units. The device is intended for diagnosing diabetes, identifying patients at risk for diabetes, and monitoring long-term blood glucose control. It operates in whole blood mode (automatic hemolysis and dilution) and dilution mode (manually hemolyzed samples).

Both the subject device and predicate use ion-exchange high-performance liquid chromatography (HPLC) operating on the same fundamental principle. The subject device measures 3.0%–15.0% HbA1c (NGSP) or 9.3–140.5 mmol/mol (IFCC), which is narrower than the predicate's 3.5%–20% (NGSP) or 15–195 mmol/mol (IFCC) range. Both accept K2-EDTA whole blood samples, employ identical standardization traceable to DCCT/IFCC and NGSP certification, and generate chromatographic peaks analyzed by software. The devices differ only in their specific hardware platforms and reagent kits, not in measurement principle or analytical approach.

The submission cites CLSI EP05-A3 (precision evaluation), CLSI EP06-A2 (linearity evaluation), CLSI EP07-A3 (interference testing), and CLSI EP09c 3rd Edition (method comparison and bias estimation). Standardization is traceable to DCCT reference methods and IFCC calibrators, with results certified through the National Glycohemoglobin Standardization Program (NGSP).

Substantial equivalence is based on identical test principles (ion-exchange HPLC), identical sample type (whole blood K2-EDTA), identical intended uses (diabetes diagnosis and monitoring), identical standardization pathway (DCCT/IFCC/NGSP), and identical regulatory classification (21 CFR 862.1373, Class II). Although the subject device's measuring range is narrower (3.0–15.0% vs. 3.5–20%), the performance validation data show it meets claimed specifications across its declared range without raising new safety or effectiveness concerns. Method comparison against a predicate-cleared device (Bio-Rad D-100) demonstrates acceptable bias and total error near clinical decision points (6.5% HbA1c), confirming the device performs equivalently within its intended scope.